Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed invasive breast cancer
• * Stage II or III disease
• * No evidence of metastasis (M0)
• * No inflammatory breast cancer (T4d)
• Must have a primary tumor
• Operable disease
• Triple-negative disease, meeting the following criteria:
• * Estrogen receptor-, progesterone receptor-, and HER2-negative by immunohistochemistry (IHC) 0 or 1+ OR fluorescence in situ hybridization negative (in case IHC is 2+)
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Pre- or post-menopausal
• Not pregnant
• Absolute granulocyte count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥10 g/dL
• Serum creatinine ≤ 1.5 mg/dL
• Total bilirubin ≤ 1.5 mg/dL
• AST/ALT ≤ 2 times normal
• Alkaline phosphatase ≤ 2 times normal
• Normal or nonspecific EKG
• LVEF ≥ 50% by MUGA or echocardiogram
• Normal mental function to understand and sign the written informed consent
• No history of uncompensated congestive heart failure
• No history of cancer except for carcinoma in situ of the uterine cervix or nonmelanoma skin cancer
• No history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
• No uncontrolled hypertension (systolic BP \> 150 mm Hg and/or diastolic BP \> 100 mm Hg)
• No history or evidence of clinically significant cardiovascular disease, including any of the following:
• * Cerebrovascular accident (CVA) or stroke within the past 6 months
• * Myocardial infarction (MI) within the past 6 months
• * Unstable angina
• * NYHA class II-IV congestive heart failure
• * Serious cardiac arrhythmia requiring medication
• No serious nonhealing wound, peptic ulcer, or bone fracture
• No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No known hypersensitivity to any of the study drugs
• PRIOR CONCURRENT THERAPY:
• No prior hormone therapy, chemotherapy, or radiotherapy for breast cancer
• No prior breast surgery other than biopsy to confirm diagnosis
• No concurrent chronic daily corticosteroids (more than 10 mg/day methylprednisolone equivalent)